Navigation Links
Cardium's InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
Date:7/15/2009

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) ("Cardium") today announced that it has entered into a definitive Asset Purchase Agreement for the acquisition of Cardium's InnerCool Therapies business ("InnerCool") by Royal Philips Electronics (NYSE: PHG, AEX: PHI). The asset purchase transaction for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables, is subject to customary closing conditions but is expected to close shortly. Once this transaction is complete the InnerCool business will operate within Philips' Healthcare sector.

(Logo:http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"The acquisition of InnerCool by Philips represents an important step forward in Cardium's overall business strategy which is focused on the acquisition, strategic repositioning and partnering or sale of businesses within our bio-medical investment portfolio. With a substantially reduced cost structure, the proceeds from this transaction will be used to enhance Cardium's balance sheet and for working capital to support the further development of Cardium's biomedical investment portfolio and product development pipeline, particularly its Excellarate(TM) Tissue Repair product candidate, which recently completed enrollment for a key clinical study," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies. "We have made significant progress in developing best-in-class products and a portfolio of innovative product opportunities, and we will continue to seek additional partnering
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
2. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
3. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
4. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
5. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
8. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
9. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
10. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
11. AACR 100th Annual Meeting Highlights Superior Ability of InNexus DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... D.C., October 9 Bavarian Nordic,the Danish-based international ... Health and Human Services (HHS) to,invoice an advance ... recent,contract (RFP-3)* to manufacture and deliver 20 million ... approved the advance payment because Bavarian Nordic fulfilled ...
... new, free white,paper, titled "A ,Six Step, ... now available for download at:, http://www.eheinc.com/labaccidents.htm . ... and often,contain a wide variety of toxic, ... imperative for any proactive health and,safety program, ...
... -, LEXINGTON, Mass., Oct. 9 Instrumentation ... Drug Administration (FDA) has,granted 510(k) clearance to expand ... venous thromboembolism (VTE) in outpatients suspected of deep,vein ... in conjunction,with a clinical pretest probability assessment model. ...
Cached Biology Technology:Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones 2Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones 3New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... , , , , , ... AUDIO: This is an audio recording of the ... Click here for more information. , , ... , , , , , ...
... (Ferrari), is considered one of the most serious ... beetle are difficult to combat; most of the insect,s ... and contact difficult. Female beetles bore holes into developing ... and create ,galleries, where they remain and deposit their ...
... /PRNewswire-iReach/ -- Global Information Inc. is excited to announce ... MA in the Spring of 2012. ... – May 4, 2012 : Cambridge Healthtech Institute is hosting ... Boston, MA. This comprehensive event encompasses 12 tracks, 15 short ...
Cached Biology News:Common North American frog identified as carrier of deadly amphibian disease 2Common North American frog identified as carrier of deadly amphibian disease 3Common North American frog identified as carrier of deadly amphibian disease 4An integrated pest management program for coffee berry borer in Colombia 2Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012 2Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012 3
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... Features A direct, ... molecules to the well surface ... , Maleic anhydride maintains its ... for months under dry, room ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
AC input: 230 V...
Biology Products: